BERMAN DENNIS N 4

What Happened Dennis N. Berman, a director of Inhibikase Therapeutics, was granted 155,000 derivative shares (reported as an award, transaction code A) on June 26, 2026. The award was reported at a $0.00 per-share acquisition price (total reported value $0) and is a compensatory equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; Filing date: 2026-06-30 (four days after the transaction).
• Instrument/price: Award of 155,000 shares at $0.00 per share (derivative/award, code A).
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting note (F1): The award vests on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to Berman’s continued service through such date.
• Timeliness: The Form 4 was filed four days after the transaction; insiders are generally required to file within two business days, so this filing may be late.

Context This is a director compensation award (routine equity grant) that vests based on continued service — not an immediate purchase or sale of stock. Such awards are common for board members and do not necessarily signal the insider’s view of near-term stock performance. Because the grant vests in the future, the shares are not immediately tradable unless further actions are taken.